Peptide Payment Processing: How to Get Approved in 2026

If you sell peptides online, you already know how this story goes. You apply for a merchant account, everything looks fine, and then the rejection email arrives. No explanation. Just a decline. Stripe, Square, and PayPal all carry blanket restrictions on peptide businesses, and their automated systems don't care that your operation is legitimate and compliant. You're left with a real business that can't take card payments.

Here's the part the rejection email never tells you: accepting payments for peptides isn't impossible. It's specialized. A narrow group of processors actually understands this vertical — how it's regulated, what the card networks require, and what makes an application approvable. ChargeAct works specifically with merchants in regulated supplement and research chemical verticals where the mainstream platforms won't go. This guide covers why approval is hard, what underwriters actually check, and what it takes to get set up and stay approved.

Why mainstream processors won't approve peptide businesses

Stripe, Square, and PayPal keep prohibited merchant lists, and peptides, research chemicals, and anything adjacent to the supplement gray zone are on them. There's no case-by-case review. The automated underwriting flags the product category and declines, and in many cases no human ever sees the application unless the merchant escalates. Stripe's restricted businesses policy and PayPal's acceptable use policy both cover this category explicitly, including research chemicals and products outside standard supplement classifications.

The flag usually trips on your product descriptions, website content, or merchant category code. Sell BPC-157, TB-500, or similar research peptides, and the content review catches it immediately. Compliant, research-use-only businesses get swept into the same filter as the sloppy ones, because the system can't tell the difference. So yes, the rejection feels unfair. Often it is.

Why does this matter? Because it stops you from wasting months. Documentation almost never overturns an explicit prohibition. The right move is to skip those platforms entirely and go straight to processors whose underwriting was built for this vertical.

What makes peptide merchant services genuinely high-risk

Research peptides sit in a legally ambiguous spot. The FDA doesn't approve most peptides as drugs or as dietary supplements, which leaves them outside the clear regulatory frameworks banks like to see. Card networks and acquiring banks translate that ambiguity into financial and reputational risk: chargebacks, refunds, the possibility of regulatory action reaching them indirectly. That risk read is baked into how every underwriter approaches the category.

The chargeback picture backs them up, to be fair. Peptide merchants run elevated dispute rates compared to standard ecommerce. The products are high-ticket, buyers sometimes dispute after delivery, and research-only positioning can genuinely confuse people at checkout. Processors typically treat dispute rates above 0.5% to 1% as a warning sign, and a few bad months can land an account in remediation or kill it. Processors who approve peptide merchants price that risk in from day one, through rates and reserves.

What underwriters actually check before approving a peptide account

Underwriters look at your storefront before they open your documents. Every product page and your homepage should carry clear "for research purposes only" and "not for human consumption" disclaimers. No therapeutic claims. No performance claims. No anti-aging language anywhere on the site. Terms of Service, Privacy Policy, Shipping Policy, and Refund Policy all need to be live and real, not placeholders. A checkout step verifying the buyer is a legitimate research customer strengthens the file considerably.

They also flag things merchants don't think about: testimonials that imply human use, influencer promotions making benefit claims, international shipping without appropriate controls. These aren't nitpicks. In our experience, website copy and compliance are the biggest failure points in declined applications. Not the products.

Documentation for peptide payment processing approval

On paper, expect to provide business registration records, EIN, government ID for all beneficial owners, and three to six months of bank statements or processing history. For the products themselves, underwriters often want a full catalog plus Certificates of Analysis showing purity and sourcing.

LegitScript certification isn't universally required, but it removes an objection during review and improves approval odds with certain acquiring banks. Per LegitScript's published pricing, the application fee is $975 per website with a $2,150 annual fee, and the process takes roughly two to four months. That clock runs separately from merchant account onboarding, so plan for it if you go that route.

Peptide payment processing costs: what to expect

High-risk processing costs more than standard ecommerce, and peptides sit toward the higher end. Transaction fees typically fall between 3.5% and 8% per card transaction. Some processors quote flat; others layer in gateway fees, monthly minimums, and PCI charges that raise the effective cost. When you compare offers, ask for the all-in number at your expected monthly volume. The headline percentage tells you very little.

Most peptide accounts also carry a rolling reserve: 5% to 15% of gross volume held for 90 to 180 days as a hedge against chargebacks and refunds. It releases on a rolling schedule, but it ties up real cash in the meantime. Chargeback fees run $25 to $100 per dispute, win or lose, which is one more reason prevention pays directly.

Reserve terms do improve. Processors typically review conditions after six to twelve months of clean processing. Keep your chargeback ratio consistently under 0.5%, keep volume stable inside your approved cap, avoid compliance issues, and you can realistically move from a 10% reserve to 5%, or from a 180-day hold to 90. That's real cash flow back in the business, and it's earned through boring, careful account management.

One more option worth adding: ACH and eCheck as a parallel payment path. Per-transaction costs are far lower than cards, often $0.20 to $1.50 per transfer, and chargeback exposure drops because ACH uses bank returns instead of card dispute mechanics. Approval is generally easier too; several processors serving this vertical report high approval rates on eCheck applications specifically.

How to find a processor that will actually approve you

Generic high-risk processors juggle dozens of merchant categories. When your peptide account hits a problem, your account manager may have never dealt with research chemical compliance, RUO labeling, or a card network inquiry about your MCC. That knowledge gap doesn't show up during the sales call. It shows up after approval, usually at the worst possible moment.

A processor with direct experience in regulated supplement and research chemical accounts can spot compliance gaps before submission and frame your application in language acquiring banks recognize. One that has boarded dozens of peptide merchants knows which disclaimers satisfy underwriters, which COA formats work, and what to say when a bank asks about the regulatory status of a specific compound. That's not marketing polish; it's the difference between a file that clears and a file that stalls.

ChargeAct works with merchants in exactly this vertical. Instead of routing applications through an automated queue, we assign a dedicated industry specialist to each account — someone who reviews your website compliance, walks you through the documentation, and handles underwriting communication directly. For peptide businesses that have been declined elsewhere, that domain-specific approach is usually the difference between another rejection and a stable account that stays approved.

The bottom line

Peptide payment processing is harder than it should be. The mainstream processors won't budge, and the requirements from specialized providers are real. But the path through is clear once you know what you're dealing with: get the website compliant before applying, have the documentation ready, and understand what fees and reserves will actually cost at your volume.

If Stripe, Square, or a generic high-risk processor has already declined you, the issue usually isn't your business. It's the fit.